These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 36853602)

  • 1. Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
    Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
    JAMA Netw Open; 2023 Feb; 6(2):e231181. PubMed ID: 36853602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naïve Adults During Delta Versus Omicron Waves.
    Doll MK; Waghmare A; Heit A; Levenson Shakoor B; Kimball LE; Ozbek N; Blazevic RL; Mose L; Boonyaratanakornkit J; Stevens-Ayers TL; Cornell K; Sheppard BD; Hampson E; Sharmin F; Goodwin B; Dan JM; Archie T; O'Connor T; Heckerman D; Schmitz F; Boeckh M; Crotty S
    medRxiv; 2022 Nov; ():. PubMed ID: 36425923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers.
    ; Thompson MG; Yoon SK; Naleway AL; Meece J; Fabrizio TP; Caban-Martinez AJ; Burgess JL; Gaglani M; Olsho LEW; Bateman A; Lundgren J; Grant L; Phillips AL; Groom HC; Stefanski E; Solle NS; Ellingson K; Lutrick K; Dunnigan K; Wesley MG; Guenther K; Hunt A; Mak J; Hegmann KT; Kuntz JL; Bissonnette A; Hollister J; Rose S; Morrill TC; Respet K; Fowlkes AL; Thiese MS; Rivers P; Herring MK; Odean MJ; Yoo YM; Brunner M; Bedrick EJ; Fleary DE; Jones JT; Praggastis J; Romine J; Dickerson M; Khan SM; Lamberte JM; Beitel S; Webby RJ; Tyner HL
    JAMA; 2022 Oct; 328(15):1523-1533. PubMed ID: 36255426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.
    Marquez C; Kerkhoff AD; Schrom J; Rojas S; Black D; Mitchell A; Wang CY; Pilarowski G; Ribeiro S; Jones D; Payan J; Manganelli S; Rojas S; Lemus J; Jain V; Chamie G; Tulier-Laiwa V; Petersen M; DeRisi J; Havlir DV
    JAMA Netw Open; 2022 Oct; 5(10):e2235844. PubMed ID: 36215069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.
    Wee LE; Lim JT; Tay AT; Chiew CJ; Ong B; Lye DCB; Lahiri M; Tan KB
    JAMA Netw Open; 2024 Aug; 7(8):e2430983. PubMed ID: 39212988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal and perinatal outcomes of SARS-CoV-2 infection in unvaccinated pregnancies during Delta and Omicron waves.
    Birol Ilter P; Prasad S; Mutlu MA; Tekin AB; O'Brien P; von Dadelszen P; Magee LA; Tekin S; Tug N; Kalafat E; Khalil A
    Ultrasound Obstet Gynecol; 2022 Jul; 60(1):96-102. PubMed ID: 35441407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history.
    Townsley H; Gahir J; Russell TW; Greenwood D; Carr EJ; Dyke M; Adams L; Miah M; Clayton B; Smith C; Miranda M; Mears HV; Bailey C; Black JRM; Fowler AS; Crawford M; Wilkinson K; Hutchinson M; Harvey R; O'Reilly N; Kelly G; Goldstone R; Beale R; Papineni P; Corrah T; Gilson R; Caidan S; Nicod J; Gamblin S; Kassiotis G; Libri V; Williams B; Gandhi S; Kucharski AJ; Swanton C; Bauer DLV; Wall EC
    PLoS One; 2024; 19(3):e0294897. PubMed ID: 38512960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
    Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
    medRxiv; 2021 Dec; ():. PubMed ID: 34909794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.
    Spiliopoulos L; Sørensen AIV; Bager P; Nielsen NM; Hansen JV; Koch A; Meder IK; Videbech P; Ethelberg S; Hviid A
    Am J Epidemiol; 2024 Aug; 193(8):1106-1114. PubMed ID: 37981717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Nakakubo S; Kishida N; Okuda K; Kamada K; Iwama M; Suzuki M; Yokota I; Ito YM; Nasuhara Y; Boucher RC; Konno S
    Lancet Infect Dis; 2023 Nov; 23(11):1244-1256. PubMed ID: 37399831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
    Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
    JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Rapid Antigen Tests' Performance Between Delta and Omicron Variants of SARS-CoV-2 : A Secondary Analysis From a Serial Home Self-testing Study.
    Soni A; Herbert C; Filippaios A; Broach J; Colubri A; Fahey N; Woods K; Nanavati J; Wright C; Orwig T; Gilliam K; Kheterpal V; Suvarna T; Nowak C; Schrader S; Lin H; O'Connor L; Pretz C; Ayturk D; Orvek E; Flahive J; Lazar P; Shi Q; Achenbach C; Murphy R; Robinson M; Gibson L; Stamegna P; Hafer N; Luzuriaga K; Barton B; Heetderks W; Manabe YC; McManus D
    Ann Intern Med; 2022 Dec; 175(12):1685-1692. PubMed ID: 36215709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022.
    Hall VJ; Insalata F; Foulkes S; Kirwan P; Sparkes D; Atti A; Cole M; de Lacy E; Price L; Corrigan D; Brown CS; Islam J; Charlett A; Hopkins S;
    J Infect; 2024 Jan; 88(1):30-40. PubMed ID: 37926119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.